Hereditary Cancer Panel denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Hereditary Cancer Panel as Experimental

UnitedHealthcare (UHC) publishes Coverage Determination Guidelines that include specific evidence-review criteria for genetic tests. An "experimental," "investigational," or "unproven" denial means that UHC determined the submitted clinical information did not satisfy its evidence standard for the specific hereditary cancer panel or the specific indication for which it was ordered. For hereditary cancer panels used in guideline-supported clinical scenarios, these denials are among the most successfully appealed.

## Why This Denial Is Appealable

Hereditary cancer panels for well-established indications — including hereditary breast and ovarian cancer syndrome, Lynch syndrome, and other hereditary cancer syndromes with recognized genetic bases — are endorsed by major professional medical societies and incorporated into current clinical guidelines. UHC's own Coverage Determination Guidelines for hereditary cancer testing contain explicit covered indications. An experimental denial frequently means either the indication was not clearly documented in the submitted request, the specific panel configuration is broader than what the policy's covered gene set describes, or the guideline supporting the indication was not cited in the prior authorization or claim submission.

All of these grounds are correctable on appeal with proper documentation.

## Federal Appeal Framework

• Internal Appeal: ACA and ERISA §503 guarantee a full-and-fair internal appeal. File within the deadline on your denial letter.
• External Review: Under ACA §2719, after a final internal denial, you are entitled to independent external review by an accredited IRO, generally within four months of the final internal denial. The IRO applies a "generally accepted standards of medical practice" standard — under which guideline-endorsed hereditary cancer panels routinely qualify. Expedited review is available for urgent oncologic situations.
• ERISA Plans: Request the complete claims file and the specific UHC Coverage Determination Guideline and version number applied.

## Concrete Appeal Steps and Timeline

1. Obtain the specific Coverage Determination Guideline version UHC applied — confirm it is current and compare your indication against the listed covered indications. 2. Obtain the current guideline from the applicable professional organization (such as NCCN) and confirm your indication is covered. 3. Have your prescriber prepare a medical-necessity letter explicitly mapping your clinical situation to the guideline's covered indication criteria. 4. File internal appeal with all supporting documentation. 5. File external review if internal appeal is upheld — UHC experimental denials are frequently overturned at external review when professional society guidelines are properly documented.

## Documentation to Gather

• Prescriber letter documenting the specific clinical indication and mapping it explicitly to the applicable professional guideline criteria
• Diagnosis records, detailed personal and family cancer history, and any prior genetic test results
• Current applicable guideline from the relevant professional organization (such as NCCN) confirming coverage of the specific indication — obtain directly from that organization's website
• Laboratory analytical and clinical validation documentation, especially if the panel includes genes beyond the most commonly tested
• The specific UHC Coverage Determination Guideline applied — request this as part of the claims file

## Criteria-Mapping Structure

For each component of the UHC experimental-denial criteria, document your response:

| Denial Component | Your Supporting Evidence | |---|---| | Indication not in covered guideline criteria | Prescriber letter; current guideline confirming indication is covered | | Panel configuration exceeds covered gene set | Clinical justification for each additional gene; prescriber letter | | Evidence standard not met | Professional society endorsement; lab validation documentation |

The most persuasive internal appeals directly quote the applicable guideline's indication criteria and show — line by line — that your clinical situation meets each element. At external review, IRO reviewers applying the ACA standard regularly find that guideline-endorsed hereditary cancer panels do not meet the definition of experimental or investigational.